hepatocelluar carcinoma
Conditions
Interventions
Group 1:The Opdivo drug treatment group will be given pd-1 inhibitor treatment once every two weeks. The dose of Opdivo drug is calculated according to 3mg/Kg body weight
Group 2:The Keytruda drug treatment group will be given Keytruda drug treatment once every three weeks, with a dose of 200mg, usage and precautions the same as Opdivo drug.
Sponsors
The Third Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) aged 18-75 years old male and female; 2) clinically diagnosed as primary liver cancer; 3) child-pugh level A liver function; 4) PS score 0-1, and the expected survival time is > for 6 months; 5) the subjects volunteered to participate in this study, signed the informed consent form, followed up with good compliance.
Exclusion criteria
Exclusion criteria: 1) suffering from other malignant tumors, organ failure or autoimmune diseases at the same time; 2) receive other immunosuppressive therapy; 3) any social/psychological problems that the researcher has determined are not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Duration of response;Progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactRuiyun Xu
The Third Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed